Vivani Medical (NASDAQ:VANI) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Vivani Medical (NASDAQ:VANI) from a sell rating to a hold rating in a report published on Saturday.

Several other research analysts also recently weighed in on VANI. Lake Street Capital started coverage on Vivani Medical in a research note on Tuesday, June 23rd. They set a “buy” rating and a $4.00 price target for the company. Weiss Ratings upgraded shares of Vivani Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $3.75.

Vivani Medical Trading Up 4.5%

NASDAQ:VANI opened at $1.40 on Friday. Vivani Medical has a 12 month low of $0.92 and a 12 month high of $1.92. The firm’s 50 day moving average is $1.29 and its 200 day moving average is $1.25. The stock has a market capitalization of $120.73 million, a PE ratio of -4.00 and a beta of 2.35.

Vivani Medical (NASDAQ:VANI) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. Research analysts predict that Vivani Medical will post -0.3 earnings per share for the current year.

Insider Activity

In other news, Director Gregg Williams acquired 1,587,301 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was bought at an average cost of $1.26 per share, for a total transaction of $1,999,999.26. Following the completion of the transaction, the director owned 36,119,086 shares of the company’s stock, valued at $45,510,048.36. The trade was a 4.60% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 53.30% of the company’s stock.

Institutional Trading of Vivani Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of VANI. Citadel Advisors LLC purchased a new stake in Vivani Medical in the 3rd quarter worth approximately $26,000. Susquehanna International Group LLP increased its holdings in shares of Vivani Medical by 100.5% in the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after purchasing an additional 16,200 shares during the period. Jane Street Group LLC bought a new position in shares of Vivani Medical in the fourth quarter worth $60,000. Renaissance Technologies LLC increased its holdings in shares of Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after purchasing an additional 53,127 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Vivani Medical in the fourth quarter worth $174,000. Institutional investors own 6.78% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.